Clinical trial

Is Labetalol More Effective Than Metoprolol for Controlled Hypotensive Anesthesia During Endoscopic Nasal Surgeries? A Randomized Clinical Trial.

Name
DTH: 22001
Description
Background: Mucosal bleeding is the most frequent complication with endoscopic nasal surgeries, as it interferes with the optimal visualization of the intranasal anatomy, leading to increased complications, operation duration, and blood loss. There are several pharmacological techniques for the appropriate control of intraoperative bleeding. Objectives: To compare the safety and efficacy of oral labetalol versus oral metoprolol as a premedication for controlled hypotensive anesthesia during endoscopic nasal surgeries. Patients and Methods: This is a randomized, double-blind, phase four, comparative clinical trial; carried out on 60 patients, who were candidates for endoscopic nasal surgeries under general anesthesia at our hospital. Patients were randomly allocated into two equal groups; group L, received oral labetalol, and group M, received oral metoprolol.
Trial arms
Trial start
2021-04-01
Estimated PCD
2022-10-01
Trial end
2022-10-15
Status
Completed
Phase
Early phase I
Treatment
Labetalol Hydrochloride Oral Tablet
Labetalol 200 mg
Arms:
Group L (n=30)
Other names:
Labipress tablets
Metoprolol Tartrate Oral Tablet
Metoprolol 100 mg
Arms:
Group M (n=30)
Other names:
Betaloc tablets
Size
60
Primary endpoint
Mean and Standard deviation of Blood loss (ml)(mean±SD)
30 minutes after the end of surgery
Eligibility criteria
Inclusion Criteria: * American Society of Anesthesiologists (ASA) physical status ≤ II * Age from 21 to 50 years * Body Mass Index (BMI) ≤ 35 kg/m2 Exclusion Criteria: * ASA physical status \> II * Age \< 21 years or \> 50 years * Pregnant women * Breastfeeding * Bronchial asthma * Chronic obstructive pulmonary disease * Hypertension * Ischemic heart disease * Rheumatic heart disease * Heart failure * Heart block * Sick sinus syndrome * Sinus bradycardia * Chronic hypotension * Anemia (Hb \< 10 g/dl) * Renal or hepatic dysfunction * Central nervous system disease * Bleeding diathesis * Diabetes Mellitus * Allergic fungal sinusitis * Patients on beta-blockers, tricyclic antidepressants, alcohol or drug abuse, anticoagulation therapy, agents influencing the autonomic nervous system * Patients using pacemakers * Allergy to the study drugs * Any contraindication of oral intake
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 60, 'type': 'ACTUAL'}}
Updated at
2023-09-28

1 organization

2 products

1 indication